Group 1 - The company, Bluestar Medical, disclosed a tax payment and interest totaling approximately 196 million yuan that needs to be repaid [2][3] - The tax adjustment relates to transfer pricing issues concerning cross-border related party transactions from 2020 to 2022 [2] - The company is expected to report a net loss attributable to shareholders ranging from 650 million yuan to 850 million yuan for 2025, indicating an increase in losses compared to 2024 [4] Group 2 - Bluestar Medical is headquartered in Zibo, Shandong, and its main business areas include cardiovascular medical consumables, health protection gloves, and emergency rescue kits [3] - The total amount of tax and interest that Bluestar Medical and its subsidiaries need to repay is approximately 195.86 million yuan as of December 31, 2025 [3]

Core Viewpoint - 蓝帆医疗预计2025年将面临6.5亿至8.5亿元的亏损，但心脑血管事业部的强劲增长和健康防护事业部的毛利率回升为未来业绩改善提供了希望 [1] Group 1: Health Protection Business - 健康防护事业部的亏损扩大主要由于固定资产减值计提和中美经贸关系波动 [2] - PVC手套出口业务在中美经贸磋商后企稳，行业价格在2025年末回升，健康防护业务的毛利率在第四季度回正 [2] - 公司通过"减重"措施集中释放不利因素，为未来利润增长奠定基础 [2] Group 2: Cardiovascular Business - 心脑血管业务的扭亏证明了公司在高值耗材领域的竞争力，冠脉药物球囊在国家集采中的表现优异 [3] - 集采政策的转变为具备创新能力的企业带来长期利好，公司的创新管线储备决定了未来增长潜力 [3] - 公司在冠脉介入领域的多款创新产品获批，CE认证的冠脉血管内冲击波治疗系统为进入全球市场提供机会 [3] Group 3: Overall Outlook - 蓝帆医疗似乎已走出利空阶段，心脑血管业务的增长提供了安全垫，健康防护业务的周期触底提供了弹性空间 [3] - 公司有望迎来业绩与估值的双重提升 [3]

Core Viewpoint - Mingde Biological is planning two acquisitions within a month, including a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for 35.7 million yuan, despite Hunan Lanyi's negative net assets and consecutive losses [1][2]. Group 1: Acquisition Details - The acquisition of Hunan Lanyi aims to enhance synergy and core competitiveness, focusing on complementary industry chains to improve comprehensive service capabilities [1][2]. - Hunan Lanyi, established in September 2020, specializes in IVD instruments and reagents, recognized as a national high-tech enterprise and a "little giant" in specialized fields [2]. - The acquisition structure includes Mingde acquiring 51% of Hunan Lanyi, while related parties will hold an additional 20%, with plans for full control if performance targets are met [2][3]. Group 2: Financial Performance and Projections - Hunan Lanyi reported a net asset of -62.42 million yuan and consecutive losses of 20.68 million yuan in 2024 and 23.98 million yuan in the first three quarters of 2025 [1]. - Mingde Biological's projected net profit for 2025 is expected to decline by 75.85% to 83.9%, ranging from 12 million to 18 million yuan, primarily due to decreased investment income and increased credit impairment losses [5]. - The financial performance of Wuhan Bikaier, another target for acquisition, shows stable revenue and profit, with 2023 revenues of 168 million yuan and net profit of 12.64 million yuan [4].

Core Viewpoint - Bluefan Medical (002382) is expected to report a significant increase in net loss for the fiscal year 2025, primarily due to various operational challenges and financial adjustments [1] Group 1: Financial Performance - As of January 30, 2026, Bluefan Medical's stock closed at 5.92 yuan, with a market capitalization of 5.962 billion yuan [1] - The company anticipates a net loss attributable to shareholders ranging from 650 million yuan to 850 million yuan for 2025, which represents an increase in losses compared to the previous year [1] - The health protection division is facing order fluctuations and price pressures due to international trade conditions, contributing to the expected losses [1] Group 2: Specific Loss Drivers - The cardiovascular division incurred a fair value loss of approximately 120 million yuan due to valuation changes in its associate company, Suzhou Tongxin [1] - The company headquarters has recognized financial expenses related to financial liabilities amounting to 100 million yuan [1] - Despite the overall losses, the cardiovascular division is expected to achieve operational profitability, excluding non-operating items [1]

（记者 张明双） 每经AI快讯，蓝帆医疗1月30日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损6.5亿 元~8.5亿元。上年同期归属于上市公司股东的净利润亏损约4.46亿元。 每经头条（nbdtoutiao）——中国无人驾驶"军团"，"武装"阿布扎比 ...

Core Viewpoint - Bluefan Medical has announced an earnings forecast indicating a projected loss per share of 0.65 to 0.85 yuan for the year 2025 [1] Group 1: Reasons for Performance Fluctuation - The company's health protection division is experiencing order fluctuations due to international trade conditions, leading to pressure on sales prices and an overall significant loss for the year despite a recovery in gross margin in Q4 2025 [2] - The health protection division is undergoing a special tax adjustment related to cross-border transactions from 2020 to 2022, resulting in tax payments and interest charges that negatively impact net profit [2] - The cardiovascular division's investment in Suzhou Tongxin Medical Technology Co., Ltd. has resulted in a fair value loss of approximately 120 million yuan due to valuation changes, although this does not involve cash outflow [2] Group 2: Performance of Cardiovascular Division - Excluding the impact of Suzhou Tongxin, the cardiovascular division has shown continuous improvement, achieving a sales revenue of approximately 1.4 billion yuan in 2025, representing over a 24% increase from the previous year [3] - The sales and management expense ratios have further decreased, contributing positively to the division's profitability [3] Group 3: Financial Impacts and Other Notes - The company is expected to incur financial expenses of 100 million yuan in 2025 due to a strategic investment in its subsidiary, which will be recognized as a financial liability [3] - The company has reported a fair value gain of approximately 13 million yuan from investments in peripheral and neuro-interventional fields, contributing to overall profit [3] - The earnings forecast is based on preliminary estimates, with final financial data to be disclosed in the official annual report [3]

Core Insights - Mingde Biological has initiated two equity acquisitions to focus on emergency rescue and in vitro diagnostic instruments, driven by declining COVID-19 testing business and increasing competition in the in vitro diagnostic industry [1][6] Group 1: Acquisition Details - On December 31, 2025, Mingde Biological signed a framework agreement with Blue Sail Medical to acquire 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. for cash [2] - Wuhan Bikaier, a leader in emergency rescue, reported a revenue of 165 million yuan and a net profit of 13.87 million yuan in 2024, with a revenue of 75.8 million yuan and a net profit of 7.52 million yuan in the first half of 2025 [2] - The acquisition aims to enhance Mingde Biological's market position in critical care by integrating emergency protection services into industrial and household scenarios [2] Group 2: Second Acquisition - On January 20, 2026, Mingde Biological announced a plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total price of 35.71 million yuan, making it a subsidiary [3][4] - Hunan Lanyi focuses on IVD instruments and has significant potential in the market, particularly in glycosylated hemoglobin testing [4] - The acquisition includes performance commitments, with Hunan Lanyi required to achieve an average net profit of at least 20 million yuan over three years to trigger further acquisition phases [5] Group 3: Financial Performance - Mingde Biological's revenue has faced significant declines, with 2023 and 2024 revenues at approximately 750 million yuan and 350 million yuan, representing year-on-year declines of 92.88% and 53.30% respectively [6] - The company reported a net profit of approximately 74.93 million yuan in 2023, down 9.22% year-on-year, and a net profit of about 74.52 million yuan in 2024, down 0.54% year-on-year [6] - As of September 30, 2025, the company's cash reserves were 184 million yuan, a decrease of 63% from the beginning of the period [6]

南财智讯1月30日电，蓝帆医疗发布2025年年度业绩预告，预计2025年全年归属于上市公司股东的净利 润为亏损6.50亿元—8.50亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏 损7.80亿元—9.80亿元。2025年由于下述主要原因综合作用，导致公司年度业绩出现波动：1、受国际贸 易形势影响，公司健康防护事业部2025年订单形势波动，同时叠加销售价格承压，尽管2025年第四季度 毛利率已回正，但全年仍呈现明显亏损。此外：①公司健康防护事业部相关主体根据税务部门要求就 2020年度至2022年度跨境关联交易转让定价相关涉税事项开展特别纳税调整自查而产生补缴税款及加收 利息事项，详见公司与本公告同日披露的《关于补缴税款的公告》（公告编号：2026-011），②公司依 据业务及市场情况对健康防护事业部固定资产进行合理减值及报废，以上两项均对健康防护事业部2025 年度净利润有明显负向影响。2、公司心脑血管事业部子公司参股投资的苏州同心医疗科技股份有限公 司（以下简称"苏州同心"）于2025年6月底完成上市前融资，其一级市场估值变动造成公司其他非流动 金融资产确认公允价值变动损失约1.2 ...

关于补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近期，蓝帆医疗股份有限公司（以下简称"公司"）及子公司根据税务部门要求， 对健康防护事业部相关主体2020年度至2022年度跨境关联交易转让定价相关涉税事项 开展特别纳税调整自查，现将有关情况公告如下： 一、基本情况 经自查，公司及子公司需就相关税务事项补缴税款 16,956.09 万元，并对应加收利 息。公司将依法按时履行补缴义务。截至本公告披露日，本次事项不涉及税务行政处罚。 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-011 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 截至2025年12月31日，公司及子公司就该事项应补缴税款及加收利息合计19,586.00 万元。扣除截至该日已预缴及已预提金额后，剩余应补缴税款及加收利息合计14,088.05 万元将计入2025年度当期损益，预计相应减少公司该年度净利润。最终会计处理结果以 公司正式披露的经审计的2025年度财务报表为准。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-012 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、预计的业绩： | | | √亏损 □扭亏为盈 □同向上升 □同向下降 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损：65,000.00 万元–85,000.00 | 亏损：44,560.89 万元 万元 | | 扣除非经常性损益 后的净利润 | 亏损：78,000.00 万元–98,000.00 | 亏损：47,985.76 万元 万元 | | 基本每股收益 | 亏损：0.65 元/股–0.85 元/股 | 亏损：0.44 元/股 | 二、与会计师事务所沟通情况 蓝帆医疗股份有限公司 2025年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、受国际贸易形势影响，公司健康 ...